"versionIdentifier","rationale","id","uuid:ID","instanceType"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","def8a780-4ad8-48c9-82e1-19a10abf8a7b","StudyVersion"
